SIGLEC1 and urinary bladder cancer: Touko Asano et al. revealed that the amount of CD169+ macrophages significantly correlated with the abundance of CD8+ cells and the favorable survival in bladder cancer, suggesting that CD169+ macrophages may play an anti-tumor role by boosting cytotoxic T-cell-mediated anti-tumor immunity [18].